Abolis Biotechnologies has introduced the Microbial Intelligence Explorer (MINE), a platform designed for cosmetics companies to better understand and utilize complex biological data, facilitating more informed decision-making in product development. This launch coincides with a growing trend in the beauty industry towards technology-driven innovation, where consumers increasingly demand sustainable and high-performance ingredients.
Read More
As brands invest in biotechnology to develop greener alternatives, they often struggle with the intricate biological information that underpins scientific innovation. R&D teams may lack effective tools to interpret multi-omics data, which MINE aims to address. The platform is targeted at cosmetics innovators, manufacturers, and R&D teams working with microbial systems who find it challenging to identify key findings relevant to formulation.
Abolis positions MINE as a means to design smarter experiments, thereby accelerating R&D and innovation. Sylvia Julien, the general manager of the MINE business unit at Abolis, noted the difficulty in integrating various biological data, emphasizing that the platform helps teams concentrate on the most critical experimental inquiries.
MINE integrates genomic exploration, multi-omics analysis, and experimental interpretation, offering insights into how different microbial strains can generate beneficial molecules for cosmetics, their interactions, and how to enhance production parameters. The platform also aligns findings with partners’ technical and industrial needs, helping users prioritize experiments that are likely to yield productive results and guiding resource allocation.
The platform originated from the Microbiome Studio, an analytical tool developed through a French government-backed industrial program. Initially built for Abolis' internal projects, it has since been refined with industry collaborations and adapted for external R&D and innovation teams.
Cyrille Pauthenier, co-founder and CEO of Abolis, remarked that the release of MINE encapsulates over a decade of experience in microbial biotechnology, creating a bridge between biological evidence and practical applications in process development. This transition enhances Abolis' ability to support decision-making before, during, and after experimentation, providing a clearer pathway from microbial potential to industrial application.
As the cosmetics sector embraces biotech innovation, MINE's launch is timely. The platform aligns with Abolis’ broader strategy of connecting microbial intelligence to its capabilities in strain engineering, enzyme modeling, and bioprocess development. This allows partners to evaluate the biological and industrial viability of various microbes.
The release of MINE comes as the cosmetics industry seeks to expedite the research and development cycle. Recent collaborations, such as the partnership between Debut and Natura to create a longevity ingredient complex using AI, underscore the importance of efficient ingredient discovery. The beauty industry faces pressure to deliver new products to consumers more quickly, prompting a push to streamline traditional R&D processes.